Improved delivery of inhaled steroids to the large and small airways  by Leach, C.L.
RESPIRATORY MEDICINE (1998) 92 (SUPPLEMENT A), 3-8 
Improved delivery of inhaled steroids to the 
large and small airways 
C.L. LEACH 
3M Pharmaceuticals, St. Paul, MN, U.S.A. 
The reformulation of asthma medications with non-ozone depleting propellants such as hydrofluoro- 
alkane-134a (HFA) has provided the opportunity to apply new knowledge and inhaler technology to 
improve significantly the delivery of aerosol drugs to the respiratory tract. Beclomethasone dipropionate 
(BDP), the most commonly prescribed inhaled corticosteroid for asthma therapy, is effective therapy; how- 
ever, currently available chlorofluorocarbon (CFC)-BDP metered dose inhalers typically deliver no more 
than 10% of the inhaled drug to the lungs with the remainder deposited in the oropharynx. Compared 
with an average particle size of 3.540 ,um for CFC-BDP, the new HFA-BDP formulation has an average 
particle size of 1.1 urn and a respirable fraction of approximately 60%. The lung deposition of 99mTc-radio- 
labelled HFA-BDP has been investigated in healthy volunteers and patients with asthma. Results showed 
that the HFA-BDP formulation reverses the pattern of distribution seen with CFCBDP products, deliv- 
ering most of the dose of inhaled steroid directly to the lungs rather than to the oropharynx and gut where 
it may lead to unwanted side-effects. As such, HFA-BDP is likely to achieve equivalent efficacy to existing 
CFC-BDP formulations with lower doses and with reduced potential for local adverse effects. 
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Introduction 
The efficacy of inhaled corticosteroids for the treat- 
ment of asthma is well documented (1). with national 
and international treatment guidelines increasingly 
recommending their use as first-line therapy for all 
except very mild asthma (2, 3). Corticosteroids for the 
treatment of asthma are usually administered by 
inhalation of an aerosol. The most common device 
used to create an aerosol for drug delivery is the 
metered dose inhaler (MDI), which contains a suspen- 
sion of drug in propellant. At present, the most com- 
monly used propellants in MDIs are pressurised 
chlorofluorocarbons (CFCs) (4). 
Successful clinical management of asthma depends 
on achieving adequate delivery of inhaled drugs to the 
lung, with anti-inflammatory agents such as cortico- 
steroids appearing to be most effective when deposited 
throughout the airways (5). However, studies have 
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shown that with CFCMDIs the proportion of the 
released dose which actually reaches the airways is 
generally less than 20%, even with optimal inhaler 
technique (6). The remainder is deposited orally, 
where it may lead to unwanted local side-effects such 
as dysphonia and oropharyngeal candidiasis, as well 
as having the potential to contribute to systemic side- 
effects if swallowed (1). 
The link between CFCs and depletion of the earth’s 
ozone layer, with the potential consequence of envi- 
ronmental damage, has led to a global phasing out of 
CFC products (7). This mandatory requirement to 
eliminate CFCs from MDIs has provided the oppor- 
tunity to apply new knowledge and inhaler technology 
to improve significantly the delivery of aerosol drugs 
to the respiratory tract. Hydrofluoroalkane-134a 
(HFA) has been identified as a substitute for CFC pro- 
pellants in pressurized MDIs (8, 9). Unlike CFC pro- 
pellants, HFA does not contain chlorine and therefore 
has no ozone-depleting potential (10). Pre-clinical 
studies have shown it to be well tolerated and to 
present no safety concerns (11, 12). 
HFA formulations of salbutamol, salmeterol and 
fluticasone propionate have been shown to be as effec- 
tive and well tolerated as existing CFC formulations at 
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equivalent dosages (13, 14). Beclomethasone dipropi- 
onate (BDP), the most commonly prescribed inhaled 
corticosteroid for asthma therapy, has also been refor- 
mulated using the new HFA propellant system 
(QvarrM, 3M Pharmaceuticals, St. Paul, MN, U.S.A.). 
Unlike CFC-MDIs, HFA-BDP is a solution, rather 
than a suspension, of drug in propellant (15). This 
means that the solution forms an extrafine aerosol of 
small droplets as the propellant evaporates. Because 
of the smaller aerodynamic diameter of the spray 
particles, this new HFA-BDP extrafine aerosol is 
expected to deliver more drug to the patient’s lungs 
and less to the throat than existing CFC-BDP formu- 
lations (5, 14, 16). 
The Importance of Particle Size 
The importance of particle size for the therapeutic 
response to inhaled bronchodilators has been recog- 
nised for some time (5, 6, 17-19). Asthma is known to 
be a disease of both large and small airways (20). 
Inhaled particles of greater than 5 pm in aerodynamic 
diameter will tend to impact and be retained in the 
oropharynx, while those with an aerodynamic dia- 
meter of less than 5 pm (often approaching 1 urn) are 
more likely to distribute and deposit in the tracheo- 
bronchial and pulmonary regions of the lungs (17, 19). 
Correspondingly, studies in asthmatic patients have 
shown the greatest pulmonary response to bron- 
chodilators to occur with particles of less than 5 urn 
diameter, presumably because of the increased 
amount of drug deposited in the airways when 
patients inhaled the smaller aerosol particles (18). 
As shown in Fig. 1, existing CFC-BDP MDIs pro- 
duce particles of approximately 3.54.0 urn in dia- 
meter and typically deliver no more than 10% of the 
inhaled dose to the lungs, with approximately 90% 
deposited in the oropharynx where it provides little 
therapeutic benefit and may lead to unwanted adverse 
effects. In contrast, the new HFA-BDP extrafine 
aerosol has an average particle size of 1.1 urn, with a 
respirable fraction of around 60% (16, 21). Animal 
and mechanical model studies suggest that this HFA- 
BDP formulation reverses the standard deposition 
pattern seen with CFC-BDP MDIs by delivering most 
of the drug to the airways and a much smaller pro- 
portion to the oropharynx and gut (21,22). 
Measuring Lung Deposition 
Comparing two formulations of the same inhaled 
glucocorticoid by conventional clinical parameters 
requires large study populations. However, alternative 
methods, such as lung deposition studies, can provide 
a valid comparison of different formulations using 
much smaller numbers of patients (23). At present, 
there are two main ways of assessing lung deposition 
of inhaled drugs in vivo (24). Pharmacokinetic studies, 
which measure drug levels in plasma or urine, give 
information on the percentage of the dose absorbed 
(as opposed to exhaled, or remaining in the spacer or 
the mouthpiece), but provide little direct information 
on the site of absorption (pulmonary or systemic). 
Alternatively, radiolabelling studies use y cameras to 
obtain images of the distribution of drug labelled with 
99mTc within the respiratory tract and lungs. 
Radiolabelling studies can be further subdivided into 
indirect and direct studies. Indirect radiolabelling 
studies use inert particles of known size such as Teflon 
microspheres, and so provide information about drug 
deposition only by inference. Direct radiolabelling 
studies use radiolabelled drug aerosols and therefore 
provide an exact model of the behaviour of drug 
particles in the lung. However, direct radiolabelling 
studies require verification before the results can be 
considered valid. In particular, in vitro validation must 
show that representative particles of all sizes are radio- 
labelled and confirm that the size distribution of the 
radiolabelled particles exactly parallels that of non- 
radiolabelled drug for each clinical dosing session. This 
ensures that the radiolabel does not distribute preferen- 
tially to particles of a certain size and thereby produce 
misleading results. Furthermore, the radiolabel must be 
shown to be stable over the period of time used. 
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FIG. 1. Comparison of CFC-BDP (B) and 
HFA-BDP (0) particle sizes. 
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A further consideration is the need for a control 
group. Comparisons between products can be per- 
formed by using parallel-group designs (where the 
control and experimental groups comprise different 
individuals), or cross-over designs (where each patient 
acts as his or her own control). The latter avoids prob- 
lems due to interindividual variability but requires 
reproducibility of inhaler technique to permit valid 
comparisons between the different study periods. The 
cross-over design also reduces the need to determine 
tissue attenuation due to y ray absorption and scatter- 
ing. This is important because no well-validated 
methods of determination of tissue attenuation exist 
for technetium-labelled lung deposition studies. 
Lung Deposition of Hydrofluoroalkane- 
134a-Beclomethasone Dipropionate 
Extrafine Aerosol 
STANDARDIZATION OF INHALATION 
PATTERN AND DRUG VALIDATION 
The lung deposition of 99mTc-radiolabelled HFA-BDP 
extrafine aerosol has been investigated in healthy 
volunteers and patients with asthma (21, 22). A criti- 
cal aspect of these studies was to ensure standardiza- 
tion of the inhalation pattern of each patient. This 
was achieved using a novel visual biofeedback system 
developed by 3M Pharmaceuticals. This respiratory 
device allowed subjects to observe a real-time visual 
display of their breath pattern (including time of 
inhalation, time to actuation and breath hold time) on 
a computer screen. Subjects could then reproduce the 
desired breath pattern for a specific comparison, 
ensuring standardization of inhaled doses. In addi- 
tion, a digitised breath pattern of the actual breath 
when the radiolabelled drug was inhaled could be col- 
lected and stored. The respiratory device in no way 
interfered with the drug delivery characteristics or 
patient ergonomics. 
An extensive validation process was followed to 
ensure the desirable association of radiolabel with 
drug. It was necessary to ensure that the mass distrib- 
ution of the formulation did not change during the 
labelling process and that the mass and radiolabel size 
distributions agreed. Radiolabelled BDP canisters 
were prepared each morning of a clinical study day. 
Andersen 1 ACFM Particle Sizing Samplers (Mark II) 
and the Quartz Crystal Microbalance Cascade 
Impactor System were used to determine these distrib- 
utions. If the distributions agreed, the formulation was 
considered to be properly labelled for the clinical 
study. 
LUNG DEPOSITION IN HEALTHY 
VOLUNTEERS 
Differences in lung deposition and distribution 
between HFA-BDP and CFC-BDP were investigated 
in an open-label pilot study involving 12 healthy male 
subjects (22). Subjects of similar physique and pul- 
monary function were selected to facilitate compara- 
bility of dosing. To be included in the study, subjects 
were also required to demonstrate excellent MD1 tech- 
nique and reproducible inspiratory technique using 
the respiratory biofeedback device. The same biofeed- 
back system was used to record the inhalation of the 
radiolabelled drug. Radiolabelling was validated using 
the method described previously. 
Products of similar ex-valve delivery (HFA-BDP 
50 ug and CFC-1 l/12 BDP 50 pg) and of similar 
expected efficacy (HFA-BDP 100 ug and CFC-1 l/12 
BDP 250 ug) were compared. Following inhalation of 
study medication, the amount of drug deposited in the 
lungs, abdomen, oropharynx and inhaler adapter, as 
well as the amount the subject expired through a filter 
trap, were measured by y scintigraphy. 
The mean percentage of total radioactivity in the 
lungs was found to be greater with the HFA-BDP 
products than with the CFC11/12 BDP products, 
with ex-actuator lung deposition of 51% and 4%, 
respectively. In contrast, deposition of BDP in the 
oropharynx was much less with both strengths of 
HFA-BDP (30%) than with CFC-11/12 BDP (94%). 
No attenuation correction was performed because 
each subject served as his own control. y camera imag- 
ing confirmed that lung deposition of BDP was 
greatest with the HFA formulation (Fig. 2). Drug 
deposition of HFA-BDP was evident throughout the 
central, intermediate and peripheral airways, while 
with CFC-BDP deposition was most evident in the 
oropharynx and large central airways. The mean mass 
of drug delivered to the lungs ex-actuator was found 
to be 20.9 and 48.9 ug for HFA-BDP 50 ug and 
HFA-BDP 100 ug, respectively. This approximately 
linear relationship between lung deposition and 
administered dose is consistent with observations in 
pharmacokinetic studies (25). 
LUNG DEPOSITION IN ASTHMATIC 
PATIENTS 
The lung deposition of radiolabelled HFA-BDP 50 ug 
delivered from a standard press-and-breathe (P&B) 
MD1 has also been evaluated in a open-label study 
involving 16 patients with mild asthma (21, 22). All 
patients demonstrated excellent technique in the use of 
the P&B MD1 and reproducibility of their inspiratory 
flow pattern using the respiratory biofeedback device. 
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FIG. 2. Comparative deposition patterns of (a) CFC-BDP and (b) HFA-BDP in healthy volunteers. 
The same biofeedback system was used to record the 
inhalation of radiolabelled drug. Radiolabelling was 
validated using the method previously described. 
Following inhalation of study medication, the 
amount of drug deposited in the lungs, upper 
abdomen, oropharynx, inhaler adapter and spacer as 
well as the amount the subject expired through a filter 
trap were measured by y scintigraphy. As in the study 
in healthy volunteers, most of the drug was delivered 
to the lungs (56%), with only a comparatively small 
quantity deposited in the oropharynx (28%). y scintig- 
raphy confirmed that BDP was distributed throughout 
the central, intermediate and peripheral airways with 
the HFA-BDP MDI, with minimal drug deposition in 
the oropharynx even without the use of a spacer 
attachment (Fig. 3). The mean drug mass delivered 
exactuator to the lungs was calculated to be approxi- 
mately 23.1 pg assuming a delivery of 41 pg per actu- 
ation. 
Discussion 
The lung deposition studies in healthy volunteers and 
asthmatic patients reviewed in this paper confirm that 
the unique formulation of the HFA-BDP extrafine 
aerosol provides greater lung deposition and less 
oropharyngeal deposition than CFC-BDP. y camera 
FIG. 3. Deposition of HFA-BDP delivered from a 
standard P&B MD1 in asthmatic patients. 
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imaging demonstrated that BDP was deposited 
throughout the central, intermediate and peripheral 
airways with the HFA formulation, while deposition 
of BDP was largely restricted to the oropharynx and 
central airways with the CFC product. Since the 
HFA-BDP extrafine aerosol delivers most of the dose 
of inhaled glucocorticoid directly to the lungs rather 
than to the oropharynx and gut, it should result in 
greater therapeutic benefit with a reduced incidence of 
oropharyngeal adverse events. 
The extensive validation methodology employed by 
these studies allows great confidence to be placed in the 
results. Validation procedures demonstrated that prod- 
uct performance remained unchanged during the radio- 
labelling process and confirmed that representative 
particles of all sizes were radiolabelled, while the use of 
the visual biofeedback respiratory device ensured con- 
sistent breathing patterns for comparison. These pro- 
cedures ensured that the inhaled dose of radiolabelled 
drug was standardized, allowing comparison of y 
scintigraphy results between subjects and study days. 
Throughout the studies, these validation methods 
confirmed that the mass distributions of both the 
HFA-BDP extrafine aerosol and the CFC-1 l/12 BDP 
formulations remained unchanged by the radio- 
labelling process. Similarly, the mass distributions of 
the unlabelled HFA-BDP products were the same as 
the radiolabel size distributions of the labelled HFA- 
BDP. However, because it is a suspension formulation, 
the mass distributions of the unlabelled CFC-11/12 
BDP products did not always precisely match the radi- 
olabel size distributions of the labelled CFC-11/12 
BDP Thus, the values obtained from CFC-BDP were 
considered less precise and were estimated to be 3-8%. 
In conclusion, the results of lung deposition studies 
confirm that HFA-BDP extrafine aerosol reverses 
the pattern of distribution seen with other steroid 
inhalers, delivering most of the drug to the airways. 
In particular, these deposition studies with HFA-BDP 
extrafine aerosol have shown improved delivery of 
inhaled steroid to the small airways. Even without 
the use of a spacer, oropharyngeal deposition was 
reduced from 90% to 30%. These improved delivery 
characteristics are likely to provide a number of impor- 
tant clinical benefits. They suggest that HFA-BDP 
extrafine aerosol will achieve equivalent efficacy to 
existing CFC-BDP formulations at a significantly 
lower total daily dose, with a reduced potential for 
local adverse effects. It also reduces the need to use a 
spacer attachment. 
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